Orlistat mouth rinse; Using the tongue to deliver antiobesity medication in a double-blind randomized crossover pilot trial

Document Type

Article

Publication Date

5-3-2023

Publication Title

Diabetes, Obesity and Metabolism

Abstract

Aim; To investigate the effects of an orlistat mouth rinse on the intake of a high-fat meal. Methods; A double-blind, balanced order, crossover study was conducted in participants (n = 10, body mass index 25-30 kg/m2) assigned to receive placebo or orlistat (24 mg/mL) prior to a high-fat meal. Participants were divided into low- or high-fat consumers based on calories consumed from fat following placebo administration. Results; The orlistat mouth rinse decreased total and fat calories consumed during the high-fat meal in high-fat consumers, and did not alter calories consumed in low-fat consumers (P < 0.05). Conclusions; Orlistat decreases long-chain fatty acid (LCFA) absorption by inhibiting lipases that breakdown triglycerides. Orlistat mouth rinse decreased fat intake in high-fat consumers, suggesting that orlistat inhibited the detection of LCFAs from the high-fat test meal. Lingual delivery of orlistat is predicted to eliminate the risk of oil incontinence and promote weight loss in individuals who prefer fat.

First Page

2236

Last Page

2242

PubMed ID

37132340

Volume

25

Issue

8

Link to Full Text

Share

COinS